Program Description:
Statement of Need
While there is no cure for most patients with glioblastoma multiforme (GBM), emerging evidence from recent research offers healthcare providers opportunities to prolong survival and improve patients’ quality of life. Use of the optimal prognostic models to improve the accuracy of disease classification and identify patients with specific genetic markers associated with treatment response to chemotherapy will ensure that patients receive the most efficacious care. In addition, patients require multidisciplinary healthcare teams that collaborate in the development of treatment plans that integrate emerging treatments for newly diagnosed GBM. The high rate of recurrence also establishes the imperative for education of healthcare providers regarding optimal second-line and salvage therapeutic options.
INTENDED AUDIENCE:
This activity is designed to meet the educational needs of physicians, pharmacists, and registered nurses involved in the care of adult glioblastoma patients.
MEDIUM:
Virtual Lecture or Podcast
Activity Objectives:
After taking part in this educational activity, participants should be better able to:
- Summarize the strengths and limitations of current treatments for newly diagnosed and recurrent glioblastoma
- Describe prognostic factors in the survival of adults with glioblastoma
- Identify molecular and genetic biomarkers associated with response to treatment
- Identify emerging targeted treatment alternatives that have demonstrated favorable results in glioblastoma
- Registered nurses and pharmacists: Provide accurate and appropriate care and counsel for patients and their families as part of the treatment
|
Credits
|
Type
|
Accreditation Statement
|
Designation Statement
|
|
1.25
|
AMA PRA Category 1 Credit(s)TM
|
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Postgraduate Institute for Medicine and RMEI, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
|
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
|
|
1.10
|
CE for Nurses
|
The Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
|
This educational activity for 1.10 contact hours is provided by Postgraduate Institute for Medicine.
|
|
1.10
|
CE for Pharmacists
|
 Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
|
Postgraduate Institute for Medicine designates this continuing education activity for 1.10 contact hours (0.11 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number – 0809-9999-12-323-H01-P)
If you participated in the live activity (Universal Activity Number - 0809-9999-12-183-L01-P), you are not eligible for this activity.
|
Faculty:
Joachim M. Baehring, MD, DSc
Director, Yale Brain Tumor Center
Associate Professor of Neurology, Medicine and Neurosurgery
Yale University School of Medicine
New Haven, Connecticut
Disclosures:
The Postgraduate Institute for Medicine (PIM) assesses conflict of interest with its instructors, planners, managers and other individuals who are in a position to control the content of CE activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. PIM is committed to providing its learners with high quality CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
Joachim M. Baehring, MD, DSc, has an affiliation with Sigma-Tau Pharmaceuticals (Speaker’s
Bureau).
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
RMEI, LLC
Emma Hitt, PhD, has no affiliations with commercial interests to disclose.
Postgraduate Institute for Medicine
The following PIM planners and managers, Laura Excell, ND, NP, MS, MA, LPC, NCC, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CCMEP, Jan Schultz, RN, MSN, CCMEP, and Patricia Staples, MSN, NP-C, CCRN, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. PIM, RMEI, LLC, and Genentech do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PIM, RMEI, LLC, or Genentech. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Accredited Provider:
This activity is jointly sponsored/co-provided by RMEI, LLC and Postgraduate Institute for Medicine
Commercial Supporter:
This activity is supported by an educational grant from Genentech.
Instructions:
Method of Participation
To complete this activity and receive a statement of credit, participants must:
1. Review all contents of this activity
2. Complete and submit the learning assessment and evaluation form
3. Score at least 70% on the learning assessment
There are no fees for participating and receiving CME credit for this activity. During the period August 27, 2012 through August 27, 2013, participants must read the learning objectives and faculty disclosures and study the educational activity.
To obtain credit, a score of 70% or better is required. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the posttest survey, and received your digital copy of your credit certificate. Your online certificate will be saved on myCME.com within your Profile/Exam History, which you can then access at any time.
For questions regarding the content of this activity, contact the accredited provider for this continuing education activity: jengelhardt@pimed.com or visit www.pimed.com. For technical assistance, contact jungsen@rmcom.net.
If you have any questions relating to your certificate or other issues with this activity, please contact myCME.Support@haymarketmedical.com.
Privacy Policy
To view RMEI privacy policy, please click here.
To view the Postgraduate Institute for Medicine privacy policy, please click here.
To view the myCME privacy policy, please click here.
SYSTEM REQUIREMENTS:
WINDOWS PC SYSTEM REQUIREMENTS:
266-MHz Pentium II; Windows 98 or higher; 64 MB RAM; 800 x 600 screen resolution
set for “High Color (16-Bit)”; Macromedia Flash Player 6 or higher.
MACINTOSH® SYSTEM REQUIREMENTS:
Power Mac g3 at 300 MHz; System 8.5 or higher (excluding Mac OSX); 96 MB RAM; 20
MB minimum hard disk space available; 800 x 600 screen resolution set to “Thousands
of Colors”; Macromedia Flash Player 6 or higher.